EDTA Chelation Study: TACT Trial Claims Lower Heart Events, What’s Real?

Posted by sleep_coastal in Research & News - 1 points, 0 comments.

I just read the TACT trial on EDTA chelation published in a cardiology journal. 5‑3 g IV CaNa₂EDTA weekly or biweekly to patients with coronary artery disease and reported a 26% drop in major cardiovascular events over two years. The article linked under /peptides/edta-chelation gives the full data.

Honestly, I think the headline is a bit bold. I’ve put a few patients on EDTA for lead exposure and noticed their fatigue ease, but that’s not the same as a heart‑attack reduction. The trial did have a decent sample size, but the numbers still feel modest, and the safety footnotes about hypocalcemia and mineral depletion are real.

I’ve seen patients drop a few milligrams of calcium after a few infusions, so I’m cautious. Do you think the risk of mineral loss outweighs the potential cardiac benefit, or can we monitor labs enough to keep it safe? Any real‑world data on patients who are on a long‑term EDTA protocol?

Community discussion - research and educational context only. Not medical advice.